Search
Beam Therapeutics Inc
BEAMAdd to Watchlist
34.320USD
-0.630-1.80%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.53BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.80%
5 Days
+3.37%
1 Month
+4.22%
6 Months
+23.81%
Year to Date
+23.81%
1 Year
+101.76%
Key Figures
34.850Open
36.060High
1.67MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.63%Turnover Ratio
34.950Prev. Close
33.621Low
44.20MTurnover
LossP/E Static
3.03P/B
0.00%Div Yield TTM
-4.48%ROA
36.44052wk High
0.51Volume Ratio
-376.74MNet Profit
102.74MShares
-0.4908EPS TTM
2.26Beta
-5.77%ROE
15.35052wk Low
6.98%Amplitude
100.00%Gross Margin
3.53BMarket Cap
2.86Reward/Risk
4.28%Risk Rate
TradingKey Stock Score of Beam Therapeutics Inc
Currency: USD Updated: 2026-06-30Key Insights
Beam Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.02.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beam Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Beam Therapeutics Inc Highlights
StrengthsRisks
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Undervalued
The company’s latest PE is -69.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 106.16M shares, decreasing 5.74% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 9.07M shares of this stock.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
50.021
Target Price
+43.12%
Upside Space
Beam Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Beam Therapeutics Inc Info
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Ticker SymbolBEAM
CompanyBeam Therapeutics Inc
CEOEvans (John M)
Websitehttps://beamtx.com/
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52146.500
-49.800 (-0.10%)
30086.800
-137.800 (-0.46%)
7471.800
-10.600 (-0.14%)
15300.000
-295.000 (-1.89%)
70736.000
-120.000 (-0.17%)
6293.400
-33.600 (-0.53%)
69.028
-0.893 (-1.28%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4030.360
+23.080 (+0.58%)
FAQs
What is the current price of Beam Therapeutics Inc (BEAM)?
The current price of Beam Therapeutics Inc (BEAM) is 34.32.
What is the symbol of Beam Therapeutics Inc?
The ticker symbol of Beam Therapeutics Inc is BEAM.
What is the 52-week high of Beam Therapeutics Inc?
The 52-week high of Beam Therapeutics Inc is 36.44.
What is the 52-week low of Beam Therapeutics Inc?
The 52-week low of Beam Therapeutics Inc is 15.35.
What is the market capitalization of Beam Therapeutics Inc?
The market capitalization of Beam Therapeutics Inc is 3.53B.
Is Beam Therapeutics Inc (BEAM) currently rated as Buy, Hold, or Sell?
According to analysts, Beam Therapeutics Inc (BEAM) has an overall rating of Buy, with a price target of 50.02.
What is the Earnings Per Share (EPS TTM) of Beam Therapeutics Inc (BEAM)?
The Earnings Per Share (EPS TTM) of Beam Therapeutics Inc (BEAM) is -0.81.